Cost-effectiveness studies of HIV vaccines. A) Incremental cost-effectiveness
ratio results from the base case of each study reviewed with error bars
representing lower and upper ranges from the sensitivity analysis; B) same as
Panel A with ICER standardized to willingness-to-pay threshold specified by
study (see Table 1).
Notes: The ICER uncertainty from Hontelez et al. is reported in one direction as
a result of the threshold analysis method to set the vaccine price, resulting in
an ICER equal to the country-specific willingness-to-pay. Three authors are
included twice to reflect different results from multiple publications (Long and
Moodley) while another presented results for two populations within one
publication (Harmon). Amirfar and Stover did not explicitly state
cost-effectiveness thresolds. The threshold from Harmon et al. was applied to
the Stover study as both model the same 26 countries. Standardized ICER
= ICER/WTP. ICER, Incremental Cost-Effectiveness Ratio. WTP, willingness
to pay per health unit gained.